PDGFRA and gastrointestinal stromal tumor: At the same time, there existed other new TKIs that have been approved by the food and drug administration (FDA) and endorsed by NCCN guidelines, for instance, avapritinib for PDGFRA D842V-mutant GIST as first-line therapy (50), and ripretinib for the progressive disease after imatinib, sunitinib, and regorafenib as fourth-line therapy (51).